What Ganirelix is
Ganirelix is a GnRH antagonist peptide used in approved fertility-medicine contexts.
Ganirelix is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it helps round out the reproductive-endocrine peptide landscape with a real approved antagonist drug.
The useful starting point is to separate the molecule itself from the internet story around it. It helps round out the reproductive-endocrine peptide landscape with a real approved antagonist drug.
Why people keep looking it up
It helps round out the reproductive-endocrine peptide landscape with a real approved antagonist drug.
Ganirelix is a GnRH antagonist peptide used in approved fertility-medicine contexts.
Ganirelix tends to stay in the conversation because it touches a familiar public theme: gnrh antagonist, fertility medicine, and pituitary signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide antagonist with direct human evidence.
Human trials and labeling support specific approved uses.
Mechanistic support follows GnRH antagonism and pituitary control.
Why this page carries the current tier: Approved peptide antagonist with direct human evidence.
The current seed trail for Ganirelix is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a regulated fertility medicine, not a generic hormone-optimization peptide.
FDA-approved ganirelix products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Ganirelix. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Ganirelix is CID 16130957. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16130957
- Formula
- C80H113ClN18O13
- Molecular weight
- 1570.3
- InChIKey
- GJNXBNATEDXMAK-PFLSVRRQSA-N
Matched synonyms include Ganirelix, 124904-93-4, Orgalutran, Ganirelixum, IX503L9WN0, DTXSID401027283, D-Alaninamide, N-acetyl-3-(1-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-N6-(bis(ethylamino)methylene)-L-lysyl-L-prolyl-, RefChem:58106.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Ganirelix returns 105 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Ganirelix returns 312 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Ganirelix Acetate
- Generic names
- GANIRELIX ACETATE
- Routes
- SUBCUTANEOUS
- Application numbers
- ANDA214996
Indications and usage. INDICATIONS AND USAGE Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Contraindications. CONTRAINDICATIONS Ganirelix acetate is contraindicated under the following conditions: Known hypersensitivity to ganirelix acetate or to any of its components including dry natural rubber/latex (see HOW SUPPLIED ). Known hypersensitivity to GnRH or any other GnRH analog. Known or suspected pregnancy (see PRECAUTIONS ).
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.